Skip to content

Study · Ex vivo tissue · 2001

4 results

[Semax and selank inhibit the enkephalin-degrading enzymes from human serum]].

Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA

Bioorganicheskaia khimiia1 May 2001Cited by 8 (Europe PMC)

PMID11443939 (opens in a new tab)DOI10.1023/a:1011373002885 (opens in a new tab)PepBankPUB-11443939
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In human serum, Semax inhibited enkephalin-degrading enzymes in a dose-dependent way, with an IC50 of 10 microM.

    In plain wordsIn lab tests, Semax blocked enzymes in human serum that break down enkephalins, and a higher dose blocked more.

    Peptide
    Semax
    Outcome
    DecreaseInhibition of enkephalin-degrading enzymes of human serum (IC50)
    Study

    humann: not reported in source

    human serum
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    10 microM
    human serum enkephalin-degrading enzymes

    Source sentences

    Summary
    Semax (IC50 10 microM)
    1 context sentence
    Summary · context
    A dose-dependent effect of synthetic heptapeptides Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) on the enkephalin-degrading enzymes of human serum was demonstrated.
  2. 02LabEx vivo tissueActivity measurement

    In human serum, Selank inhibited enkephalin-degrading enzymes in a dose-dependent way, with an IC50 of 20 microM.

    In plain wordsIn lab tests, Selank blocked enzymes in human serum that break down enkephalins, and a higher dose blocked more.

    Peptide
    Selank
    Outcome
    DecreaseInhibition of enkephalin-degrading enzymes of human serum (IC50)
    Study

    humann: not reported in source

    human serum
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    20 microM
    human serum enkephalin-degrading enzymes

    Source sentences

    Summary
    Selank (IC50 20 microM)
    1 context sentence
    Summary · context
    A dose-dependent effect of synthetic heptapeptides Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) on the enkephalin-degrading enzymes of human serum was demonstrated.
  3. 03LabEx vivo tissueActivity measurement

    In human serum, Semax inhibited enkephalin-degrading enzymes more strongly than puromycin, bacitracin and some other peptidase inhibitors.

    In plain wordsIn lab tests, Semax blocked enkephalin-degrading enzymes in human serum more strongly than puromycin, bacitracin and some other enzyme blockers.

    Peptide
    Semax
    Outcome
    DecreaseEnkephalinase inhibition versus puromycin and bacitracin
    Study

    humann: not reported in source

    human serum
    Comparator
    Puromycin, bacitracin and other peptidase inhibitors
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    10 mM
    puromycin

    Source sentences

    Summary
    The inhibitory effects of Semax (IC50 10 microM) and Selank (IC50 20 microM) are more pronounced than those of puromycin (IC50 10 mM), bacitracin, and some other inhibitors of peptidases.
  4. 04LabEx vivo tissueActivity measurement

    In human serum, Selank inhibited enkephalin-degrading enzymes more strongly than puromycin, bacitracin and some other peptidase inhibitors.

    In plain wordsIn lab tests, Selank blocked enkephalin-degrading enzymes in human serum more strongly than puromycin, bacitracin and some other enzyme blockers.

    Peptide
    Selank
    Outcome
    DecreaseEnkephalinase inhibition versus puromycin and bacitracin
    Study

    humann: not reported in source

    human serum
    Comparator
    Puromycin, bacitracin and other peptidase inhibitors
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    10 mM
    puromycin

    Source sentences

    Summary
    The inhibitory effects of Semax (IC50 10 microM) and Selank (IC50 20 microM) are more pronounced than those of puromycin (IC50 10 mM), bacitracin, and some other inhibitors of peptidases.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:04 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.